Jubilant Pharmova: Unclaimed Dividends & Shares Due for IEPF Transfer by Oct 31
Jubilant Pharmova will transfer unpaid dividends and shares to IEPF by October 31, 2026. Shareholders must claim by August 31, 2026. This includes unclaimed dividends from FY 2018-19 and old share certificates. Details are on the company website.
This is a standard regulatory process for unclaimed shareholder assets and does not directly impact the company's ongoing operations or financial performance. It primarily affects a small subset of shareholders who have not claimed their dividends or shares.
The announcement is a routine compliance communication regarding the transfer of unclaimed dividends and shares to the IEPF, as mandated by law. It does not contain positive or negative financial news.
Jubilant Pharmova Limited has informed shareholders about the upcoming transfer of unpaid/unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). This action is in accordance with Section 124(6) of the Companies Act, 2013, and the IEPF Rules. Dividends for the financial year 2018-19 that remain unpaid are due for transfer to the IEPF on October 31, 2026.
Shareholders are urged to claim their unpaid dividends and unclaimed equity shares by submitting an application to Alankit Assignments Limited by August 31, 2026. Failure to do so will result in the transfer of these dividends and shares to the IEPF Authority. The company also noted that old Rs. 10 and Rs. 5 denominated share certificates from previous entities like Ramganga Fertilizers Limited, Vam Organic Chemicals Limited, and Jubilant Organosys Limited, which were not surrendered for new Re. 1 denominated certificates, were transferred to a suspense account in 2012 and are also subject to these transfer provisions if unclaimed.
Details regarding the unpaid dividends and shares to be transferred are available on the company's website, www.jubilantpharmova.com. Shareholders can claim their transferred dividends and shares from the IEPF Authority by filing Form IEPF-5.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.